Hugel
Financials
Valuation Metrics
Hugel's Market Cap is ₩3.2T. At end of 2025 it was ₩2.9T. Ranked #136 of 2,436 in KR market (top 6%), #19 of 1,649 on KOSDAQ (top 1%), #14 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 3.23T KRW | KR#136/2,436 Sec#14/234 |
| Revenue | 451.93B KRW | KR#646/2,436 Sec#33/234 |
| Net Income | 156.69B KRW | KR#158/2,436 Sec#9/234 |
| Total Assets | 1.08T KRW | KR#451/2,436 Sec#26/234 |
| Net Assets | 980.16B KRW | KR#288/2,436 Sec#17/234 |
| Employees | 609 | KR#410/2,436 Sec#35/234 |
| Value | ||
| P/E | 20.61x | KR#1,116/2,436 Sec#66/234 |
| P/B | 3.29x | KR#2,146/2,436 Sec#171/234 |
| PEG | 0.65x | KR#709/2,436 Sec#44/234 |
| P/S | 7.14x | KR#2,217/2,436 Sec#151/234 |
| EV/EBITDA | 14.35x | KR#833/2,436 Sec#47/234 |
| FCF Yield | 4.23% | KR#920/2,436 Sec#50/234 |
| Profitability | ||
| ROE | 15.99% | KR#208/2,436 Sec#14/234 |
| ROA | 14.55% | KR#85/2,436 Sec#11/234 |
| Op. Margin | 46.36% | KR#18/2,436 Sec#3/234 |
| Revenue Growth | 29.86% | KR#478/2,436 Sec#45/234 |
| Earnings Growth | 31.47% | KR#681/2,436 Sec#43/234 |
| Financial Health | ||
| Debt Ratio | 109.86% | KR#435/2,436 Sec#62/234 |
| Total Debt | 26.00B KRW | KR#1,253/2,436 Sec#100/234 |
| FCF | 136.66B KRW | KR#144/2,436 Sec#6/234 |
| Cash | 249.30B KRW | KR#240/2,436 Sec#8/234 |
| Current Ratio | 7.49x | KR#171/2,436 Sec#41/234 |
| Net Debt/EBITDA | -1.07x | KR#445/2,436 Sec#25/234 |
| Performance | ||
| 1Y Return | -20.74% | KR#1,285/2,436 Sec#107/234 |
| 1M Return | 1.18% | KR#766/2,436 Sec#69/234 |
| From 52W High | -30.08% | KR#403/2,436 Sec#27/234 |
| 1Y MDD | -44.85% | KR#697/2,436 Sec#56/234 |
| Trading | ||
| Volume | 50,802 shares | KR#1,318/2,436 Sec#130/234 |
| Foreign Own. | 56.42% | KR#22/2,436 Sec#1/234 |
| Per Share | ||
| EPS | 12,242 KRW | KR#68/2,436 Sec#7/234 |
| BPS | 92,882 KRW | KR#138/2,436 Sec#7/234 |
Company Info
Established in 2001, this global medical aesthetics company listed on KOSDAQ in 2015 and absorbed Hugel Pharma in 2018. Its core business involves the research, development, manufacturing, and sales of Type A botulinum toxin and hyaluronic acid fillers, including products like BOTULAX, The Chaeum, and Wellage. The company drives innovation through technologies such as artificial intelligence and robotics, providing comprehensive solutions for diverse aesthetic needs to enhance corporate value. Hugel was established in 2001 and is headquartered in Chuncheon-si, Gangwon Special Self-Governing Province.